Coronavirus stock hype proves infectious
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
Crunch time for the new Parkinson’s hopes
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Tirzepatide’s time to shine for Lilly
Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.
The sellside falls out of love with Opdivo
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
Bioresorbable scaffolds flounder as Reva heads to bankruptcy
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
Why a 2020 spotlight will fall on tafasitamab
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
Plenty of choice remains for buyers of gene therapy
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Gene therapy clinical holds take centre stage
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
Meril Life Sciences comes late to aortic valves
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
